AstraZeneca said Friday that its experimental oral breast cancer drug camizestrant did not meet the main goal in a pivotal study evaluating it as a first-line therapy. The SERENA-4 trial compared the agent, given with another treatment, against the current standard of care and found no improvement in the length of time patients lived without disease progression.
The study enrolled people with ER-positive, HER2-negative breast cancer that had advanced beyond the breast and who had not received systemic therapy for their advanced disease. In that population, camizestrant plus the partner drug failed to show superiority on progression-free survival, the trial’s primary endpoint, a result that will constrain how the medicine can be used clinically.
Camizestrant had earlier this month secured accelerated approval in the United States under the brand name Etcamah for a more narrowly defined group of patients whose tumors develop a mutation associated with emerging resistance to prior treatment. That limited approval is distinct from the broader first-line population tested in SERENA-4; the negative pivotal outcome reduces the evidence supporting expansion of the drug’s label beyond the existing U.S. indication.
The company has reported the top-line SERENA-4 result publicly. Observers say the outcome has immediate implications for regulatory prospects and commercial positioning: without positive pivotal data in the untreated advanced setting, camizestrant’s use will be more tightly focused on the population covered by the accelerated U.S. approval and on settings supported by other controlled studies. For further reporting and ongoing updates on this development, readers can consult official statements from FDA and the company website.
